Login to Your Account



U.S. FILING BY END OF YEAR

Regeneron, Sanofi: anti-PCSK9 alirocumab rocks 9 lipid trials in phase III

By Randy Osborne
Staff Writer

Wednesday, July 30, 2014
With partner Sanofi SA, Regeneron Pharmaceuticals Inc. opened investors' eyes wider by making public the positive outcomes of nine phase III trials with alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in hypocholesterolemia.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription